(00:31)
 Could each of you please provide a little bit of background about yourself?

(01:18)
 Let's start with a general definition of primary ciliary dyskinesia (PCD) for our audience.

(02:21) 
 PCD is rare. Dr. Maleszewski, can you talk about the implications of that?

(02:39)
 What is the current state of PCD diagnosis in the U.S. and globally, and what are the implications for patient care?

(03:37)
 Can you say a bit more about Mayo Clinic's diagnostic approach to PCD?

(05:16)
 Mayo Clinic is the first and only diagnostic center of excellence accredited by the primary PCD foundation. What is the significance of that?

(07:01)
 Can you expand upon future plans for PCD diagnosis at Mayo Clinic?

(00:32) 
 Would you mind sharing a bit about yourself and your background?

(01:44)
 Would it be fair to say you're an expert on this topic?

(01:57)
 Could you help us understand the role of laboratory testing in supporting recovery from alcohol use disorders, and how to approach testing for those patients?

(04:50)
 Could you help us understand our new direct alcohol biomarker test and its benefits?

(07:57)
 What other tests are available, and how do they compare with this biomarker?

(00:31)
 Can you both tell us a little bit about yourselves and your backgrounds? Dr. Moyer, do you want to start?

(01:51)
 Your background, Dr. Janetto?

(02:47) 
 Please provide an overview of major depressive disorder and the test that Mayo Clinic Laboratories has available for therapeutic drug monitoring as well as pharmacogenomics.

(07:05)
 Which patients should have this testing, and when should it be performed?
 
(11:33)
 What alternative test options are available, and how do they compare?

(15:37)
 How are the results used in patient care?

(00:31)
 Would each of you share a little about yourselves and your backgrounds?

(01:17)
 Could you please provide us with an overview of what types of genetic testing for inherited kidney diseases are available Mayo Clinic Labs?

(02:35) 
 Can you expand on why genetic testing for kidney disease is important?

(04:30)
 Who could benefit from genetic testing for inherited kidney diseases?

(05:55)
 What types of variants are detected by these new genetic panels at Mayo Clinic Labs?

(07:05)
 How would you say our test matches up to other tests that are currently available?

(08:07)
 What other unique features set the Mayo test apart from some of the competitor offerings?

(09:08)
 Could you summarize the benefits of doing genetic testing for kidney diseases at Mayo Clinic?

(10:01)
 How can a healthcare provider order one of these new inherited kidney disease genetic test panels, and what types of specimens do we accept?

(00:32) 
 Would you mind telling our listeners a little about yourself and your background?

(01:16)
 This evaluation is about CIDP — chronic inflammatory demyelinating polyneuropathy, correct?

(02:16)
 Can you give us an overview of what the CIDP evaluation will consist of?

(04:38)
 Our standalone test for neurofascin-155 won't change, but will be rolled into this new test along with contactin-1, correct?

(06:41)
 This is a very rare disease with subtle clues, so does it make logical sense to pair these two antibodies?

(08:07)
 Why did we choose a cell-binding assay over a western blot or other methodology? Is there a reason why contactin-1 is better on CBA methodology?

(09:40)
 Can you elaborate on what this phenotype-specific approach means for neurologists, and how it makes their ordering easier?

(11:14)
 Even though it's hard to determine exactly what test to order for these patients, testing too broadly can just add to the confusion. Is a narrowed evaluation that answers specific questions more helpful?

(14:42)
 Can you give us any clues as to when a physician shouldn't order this test because it's unlikely to be positive?

(15:51)
 How does this test drive patient care? A lot of these patients are therapy refractory. What would be the second- or third-level treatment? Is there any oncological association with antibody positivity?

(18:44)
 Are there any alternative options for diagnostic answers for this challenging patient population?

(20:44)
 What is the key takeaway? What excites you most about this new test launch?

(00:31) 
 Could you tell us a bit about yourself and your background?

(01:11)
 Could you describe these new tests and when it would be appropriate to use each of them in the clinic?

(03:16)
 Could you provide a little background on why MCL is making changes to the PLA2R test?

(04:34)
 Could you describe the change to KDIGO guidelines and when it may be appropriate to skip the biopsy? How will these new tests help physicians implement these new guidelines in their practices?